Publication of the 2011 Registration Document

Paris, April 25, 2012 – BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that its 2011 Registration Document, has been registered with the French Market Authorities *(Autorités des Marchés Financiers)* on April 24, 2012.

The Registration Document is available to the public free of charge upon request as per current legal regulations at BioAlliance Pharma's headquarters - 49 Boulevard du Général Martial Valin, 75015 Paris - and may be consulted at the *http://www.bioalliancepharma.com* website (under Investors/Publications).

The annual financial report, the report of the Chairman of the Board of Directors on corporate governance and on internal control and risk management procedures, as well as the related auditors' report, Information on the fees paid to the statutory auditors in 2011, are included in the 2011 Registration Document.

About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:
Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)
Sitavir® (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status
Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Authorization for Phase III clinical trial
Clonidine Lauriad™ (mucositis): Phase II on going
AMEP™ (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 76 00
judith.greciet@bioalliancepharma.com
Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com